Prescription drug · ANDA
etodolac NDC 83980-030
Etodolac 500 mg/1 · Tablet · Oral · Ipca Laboratories Limited
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 83980-030-01 | 83980003001 | 100 TABLET in 1 BOTTLE (83980-030-01)Marketed from Feb 13, 2026 | |
| 83980-030-05 | 83980003005 | 500 TABLET in 1 BOTTLE (83980-030-05)Marketed from Feb 13, 2026 | |
| 83980-030-13 | 83980003013 | 30 TABLET in 1 BOTTLE (83980-030-13)Marketed from Feb 13, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- etodolac
- Generic name (nonproprietary)
- etodolac
- Active ingredients
- Etodolac — 500 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Ipca Laboratories Limited
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 204729
- Marketing start
- Listing expires
- Other FDA classes
- Non-Steroidal (Chemical structure)Cyclooxygenase Inhibitors (Mechanism)
- Identifiers
- Product ID 83980-030_4064e892-4c7a-46a7-9114-3e2bf466e597SPL ID 4064e892-4c7a-46a7-9114-3e2bf466e597SPL set ID f50a93ca-584a-4205-a79b-31bafdd309c2RxCUI 197686, 199390UNII 2M36281008
- Pharmacologic class
- Nonsteroidal Anti-inflammatory Drug
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N483980003001followed by a unit qualifier and the quantityPackage 83980-0030-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
INDICATIONS AND USAGE Carefully consider the potential benefits and risks of etodolac tablets, and other treatment options before deciding to use etodolac tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Etodolac tablets are indicated: • For acute and long-term use in the management of signs and symptoms of the following: 1. Osteoarthritis 2. Rheumatoid arthritis • For the management of acute pain
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 204729
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| etodolac | Etodolac 400 mg/1 | TabletOral | Ipca Laboratories Limited | 83980-029 |
- openFDA data updated
Med-Code stores this record for up to 24 hours before requesting it again.
Reference information only. Verify codes and billing rules against the applicable payer and official source before submitting a claim. How Med-Code handles data.